We have examined the roles of the endothelin-converting enzyme-1 and -2 (ECE-1 and ECE-2) in the homeostasis of asynuclein (a-syn) and pathogenesis of Lewy body disease. The ECEs are named for their ability to convert inactive big endothelin to the vasoactive peptide endothelin-1 (EDN1). We have found that ECE-1 and ECE-2 cleave and degrade a-syn in vitro and siRNA-mediated knockdown of ECE-1 and ECE-2 in SH-SY5Y neuroblastoma cells significantly increased a-syn both intracellularly (within the cell lysate) (p < 0.05 for both ECE-1 and -2) and extracellularly (in the surrounding medium) (p < 0.05 for ECE-1 and p = 0.07 for ECE-2). Double immunofluorescent labelling showed co-localization of ECE-1 and ECE-2 with a-syn within the endolysosomal system (confirmed by a proximity ligation assay). To assess the possible relevance of these findings to human Lewy body disease, we measured ECE-1 and ECE-2 levels by sandwich ELISA in post-mortem samples of cingulate cortex (a region with a predilection for Lewy body pathology) in dementia with Lewy bodies (DLB) and age-matched controls. ECE-1 (p < 0.001) and ECE-2 (p < 0.01) levels were significantly reduced in DLB and both enzymes correlated inversely with the severity of Lewy body pathology as indicated by the level of a-syn phosphorylated at Ser129 (r = À0.54, p < 0.01 for ECE-1 and r = À0.49, p < 0.05 for ECE-2). Our novel findings suggest a role for ECEs in the metabolism of a-syn that could contribute to the development and progression of DLB. Keywords: a-synuclein, dementia with Lewy bodies, ECE-1, ECE-2, endothelin-converting enzyme. (Mishizen-Eberz et al. 2003 ) and kallikrein-6 (KLK6) (Iwata et al. 2003; Kasai et al. 2008) . These are expressed within the cytosol, or are released extracellularly, whereupon they are activated and are likely to interact with and degrade distinct pools of a-syn that are important in the accumulation and transneuronal spread of pathogenic a-syn (Mougenot et al. 2011 (Mougenot et al. , 2012 Luk et al. 2012; MasudaReceived July 14, 2016; revised manuscript received January 17, 2017; accepted January 26, 2017. Address correspondence and reprint requests to James Scott Miners, Dementia Research Group, University of Bristol, Level 1, Learning and Research, Southmead Hospital, BS10 5NB, UK. E-mail: Scott. Miners@Bristol.ac.uk
Abnormal aggregates of a-synuclein (a-syn) within neuronal perikarya (as Lewy bodies) and neurites (as Lewy neurites) are the defining neuropathological hallmarks of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Accumulation of insoluble (Campbell et al. 2000) and soluble oligomeric a-syn (Paleologou et al. 2009 ) in sporadic PD and DLB, without an increase in a-syn mRNA (Wirdefeldt et al. 2001; Kingsbury et al. 2004) , suggest a major role for impaired clearance in the pathogenesis of these diseases. Dysregulation of the ubiquitin-proteasome system and the autophagy-lysosomal pathway probably contributes to the accumulation of a-syn, particularly in familial Lewy body disease (reviewed in Deleidi and Maetzler 2012; Ebrahimi-Fakhari et al. 2012; Webb et al. 2003; Xilouri et al. 2013) . Cathepsin D (CTSD), the major lysosomal protease responsible for a-syn cleavage (Qiao et al. 2008; Sevlever et al. 2008; Cullen et al. 2009) , is up-regulated in PD and DLB (Yelamanchili et al. 2011) . A small number of non-lysosomal proteolytic enzymes have been identified that cleave a-syn in vitro, including MMP-3 (matrix metalloproteinase 3), À9 (Sung et al. 2005) , calpain-1 (CAPN1) (Mishizen-Eberz et al. 2003 ) and kallikrein-6 (KLK6) (Iwata et al. 2003; Kasai et al. 2008) . These are expressed within the cytosol, or are released extracellularly, whereupon they are activated and are likely to interact with and degrade distinct pools of a-syn that are important in the accumulation and transneuronal spread of pathogenic a-syn (Mougenot et al. 2011 (Mougenot et al. , 2012 Luk et al. 2012; Masuda-Suzukake et al. 2013) . We reported previously that the levels of CAPN-1 and KLK6 are reduced in the cingulate cortex in DLB (Miners et al. 2014a) .
Endothelin-converting enzymes (ECE; EC number 3.4.24.71) are type II membrane metallopeptidases named for their ability to convert the inactive precursor big endothelin to endothelin-1, a potent vasoactive peptide. ECE-1 and ECE-2 share 59% sequence homology and cleave a similar range of substrates although ECE-1 is most active at a neutral pH, whereas ECE-2 is most active at a mildly acidic pH (Emoto and Yanagisawa 1995) . ECE-1 is expressed abundantly in endothelial cells in all organs but has also been identified within non-vascular cells within the CNS such as pyramidal neurons, cerebellar Purkinje cells and astrocytes (Naidoo et al. 2004; Palmer et al. 2010) . Four isoforms of ECE-1 have been identified b, c, d) : ECE-1a and ECE-1c reside within the plasma membrane (Schweizer et al. 1997; Muller et al. 2003) , whereas ECE-1b and d are located within intracellular compartments including the endolysosomal system (Schweizer et al. 1997; Azarani et al. 1998; Muller et al. 2003) . ECE-1 degrades a variety of neuropeptides (substance P, bradykinin, neurotensin, somatostatin, etc.) intracellularly within endosomes at a mildly acidic pH (Johnson et al. 1999; Fahnoe et al. 2000; Roosterman et al. 2008; Cattaruzza et al. 2009; Cottrell et al. 2009; Hasdemir et al. 2012) . ECE-2 is mostly expressed in neural tissue and has been predominantly detected in pyramidal neurons but is also expressed in astrocytes and microglia (Palmer et al. 2010 ). All four ECE-2 variants are located within intracellular secretory vesicles and they too are capable of intracellular neuropeptide degradation in mildly acidic conditions (Pacheco-Quinto and Eckman 2013; Gupta et al. 2015) . The expression and function of ECE-2 is not yet fully characterized.
ECEs hydrolyse amyloid-b (Ab) peptide in vitro (Eckman et al. 2001) and have been implicated in the pathogenesis of Alzheimer's disease (AD). Endogenous Ab levels were elevated in ECE knockout mice (Eckman et al. 2003) . A recent study reported that ECEs degrade two distinct pools of intracellular Ab: ECE-2 cleaved an intracellular pool within the autophagic and endolysosomal pathway, whereas ECE-1 predominantly degraded a pool of Ab destined for secretion (Pacheco-Quinto and Eckman 2013) . In this study, we have shown that ECE-1 and ECE-2 degrade a-syn in vitro, regulate intracellular and extracellular a-syn in SH-SY5Y cells, and have explored the hypothesis that a reduction in ECE activity contributes to the pathogenesis of DLB.
Materials and methods

Study cohort
Brain tissue was obtained from the South West Dementia Brain Bank, University of Bristol, with local Research Ethics Committee approval (08/H0106/28 + 5). The brains had been separated midsagittally -the left half sliced and frozen at À80°C and the right half fixed in formalin for paraffin histology and detailed neuropathological examination. We examined 11 pure DLB cases and 15 control brains matched for age, gender and post-mortem delay (Table 1 ). The DLB group had an average age-at-death of 77.7 AE 8.9 years and a post-mortem delay of 28.2 AE 10.3 h and consisted of five females and six males. The controls had an average age-at-death of 80.4 AE 10.0 years and a post-mortem delay of 30.0 AE 16.8 h and consisted of three females and 12 males. The MRC (Medical Research Council) identifier numbers for each case are supplied in Table S1 .
Sample size calculations, power analysis, blinding and randomization procedures were not performed in this study. We selected 11 pure DLB cases based on a diagnosis according to consensus neuropathological criteria (McKeith et al. 2005) . All DLB cases had Braak stage 5 or 6 Lewy body pathology (Braak et al. 2003) and cases were excluded on the basis of a neuropathological diagnosis of AD based on the National Institute on Aging-Alzheimer's Association guidelines for the neuropathological assessment of AD (Montine et al. 2012) or the presence of a neurodegenerative disease apart from DLB. They were also excluded if there was evidence of severe cerebral amyloid angiopathy or any other significant cerebrovascular disease. Controls had no history of dementia and no neuropathological abnormalities apart from mild neurofibrillary tangle pathology (Braak tangle stage III or less) and scattered diffuse Ab plaques in some cases.
Brain tissue
Cortical brain tissue (~200 mg), dissected from the cingulate cortex (Brodmann area 24), was homogenized in 1% NP-40 buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 2 mM 1,10-phenanthroline, 0.1 M phenylmethylsulfonyl fluoride, 1.7 mg/mL aprotinin, NP-40 detergent) in a Precellys 24 homogenizer (Stretton Scientific, Derbyshire, UK) with 2.3 mm silica beads (Biospec, Glasgow, UK). The homogenates were centrifuged at 12,470 g for 15 min at 4°C and the supernatant (soluble extract) removed, aliquoted and stored at À80°C. Insoluble pelleted material was solubilized by vigorous agitation in 6 M GuHCl (insoluble extract) and left for 4 h at room temperature (RT) before storage at À80°C. Total protein concentrations were determined using the Total Protein Kit (Sigma Aldrich, Dorset, UK) following the manufacturer's guidelines.
Assessment of cleavage of a-syn in vitro Recombinant human full-length wild-type a-syn (5 ng) (rPeptide; Stratech, Suffolk, UK) was incubated with recombinant human ECE-1 or ECE-2 (50-1.56 ng) (R&D systems, Oxford, UK) at 37°C with shaking (300 rpm) in a non-binding black 96-well plate. The reaction was performed either at a neutral pH (phosphate-buffered saline, PBS or water) or in a mildly acidic assay buffer for ECE-1 (0.1 M MES, 0.1 M NaCl, pH 6.0) and ECE-2 (0.1 M MES, and probed with mouse anti-human a-syn (syn-1) (1 in 1000) (BD Biosciences, Oxford, UK) diluted in 5% non-fat dried milk/ TBS-T (1 : 1000, at 4°C overnight with agitation). The membrane was washed in TBS-T (3 9 15 min, with agitation) and incubated with anti-mouse peroxidase-conjugated secondary antibody (Vector labs, Burlingame, CA, USA) diluted in 5% non-fat dried milk/TBS-T (1 : 4000, 2 h, 21°C, with agitation). Membranes were washed in TBS-T (3 9 15 min, with agitation) and immune-labelled proteins visualized using the Enhanced Chemiluminescence Detection System (Amersham Biosciences, Buckinghamshire, UK). Enhanced chemiluminescence detection reagents were applied (5 min) and membranes were visualized using the ChemiDoc XRS+ system (Biorad). Volumetric analysis of the relative band density was performed using Image Lab 5.0 software. The integrated area density of the band representing monomeric a-syn (~16 kDa) was measured at each time point and expressed as a percentage change relative to 0 min (i.e. before cleavage, which was assigned a value of 100%).
ECE-1 and ECE-2 sandwich ELISAs ECE-1 protein level was measured in NP-40-soluble brain tissue extracts (total protein 10 lg) and SH-SY5Y cell lysates (total protein 30 lg) using a commercially available sandwich ELISA kit (catalogue number SEA483Hu) (USCN, Wuhan, Hubei Province, China) and was interpolated from a standard curve generated from a serial dilution of recombinant human ECE-1 (2000À31.25 pg/mL). Measurements for each sample were made in duplicate. ECE-2 protein level was also measured by a commercially available sandwich ELISA kit (catalogue number CSB-EL007372HU) (Cusabio, Wuhan, Hubei Province, China). ECE-2 concentration in brain tissue extracts (total protein 25 lg) and SH-SY5Y cell lysates (total protein 25 lg) was interpolated from a standard curve produced by serial dilution of recombinant human ECE-2 (3000À46.8 pg/mL) and measured in duplicate.
a-syn and a-syn-P129 sandwich ELISAs a-syn and a-syn-P129 levels were measured by sandwich ELISA in GuHCl-solubilized brain tissue extracts and SH-SY5Y cell lysates, as previously described (Miners et al. 2014a,b; Swirski et al. 2014) For the a-syn ELISA, a mouse monoclonal anti-a-syn antibody (Syn-1, raised against epitope corresponding to aa 91-99 (Perrin et al. 2003 ) (0.5 lg/mL) (BD Biosciences) was used as the capture antibody and a biotinylated goat polyclonal anti-a-syn (raised against full-length recombinant human a-syn) (1 lg/mL) (R&D systems) was used as the detection antibody. Total a-syn concentration in brain tissue extracts (diluted 1 in 99 in PBS) and SH-SY5Y cell lysates (total protein 8 lg) was determined following interpolation from a standard curve produced from a serial dilution of recombinant human a-syn (62.5À0.97 ng/mL) (rPeptide; Stratech).
The a-syn-P129 ELISA was performed as previously described (Miners et al. 2014a,b) . Briefly, a mouse monoclonal anti-a-syn antibody (syn-1) (0.5 lg/mL) (BD Biosciences) was used as the capture antibody and biotinylated anti-a-syn-129 (0.8 lg/mL; Abcam, Cambridge, UK) as the detection antibody. a-syn-P129 concentration was determined in brain tissue extracts (diluted 1 : 99 in PBS) and SH-SY5Y cell lysates (total protein 8 lg) following interpolation against a standard curve produced from a serial dilution of recombinant a-syn (200-3.25 ng/mL) (rPeptide; Stratech) that had been phosphorylated at serine 129 by incubation with casein kinase II (New England Biolabs, Hitchin, UK) for 1 h at 30°C in the presence of ATP (New England Biolabs) as previously described (Miners et al. 2014a; Swirski et al. 2014) . The specificity of the ELISA for a-syn-P129 was previously demonstrated (Miners et al. 2014a; Swirski et al. 2014) .
SH-SY5Y cell culture and transient siRNA-mediated knockdown of ECE-1 and ECE-2 SH-SY5Y cells [American Type Culture Collection (ATCC, CRL-2266)] and SH-SY5Y cells transfected with full-length human wild-type a-synuclein (SH-SY5Y-a-syn) were maintained in Ham's F12 nutrient mixture (F12) (42% vol/vol), Eagle's minimum essential medium (42% vol/vol) supplemented with foetal calf serum (15% vol/vol), 2 mM L-glutamine, non-essential amino acids solution (1% vol/vol), penicillin (20 units/mL)/ streptomycin (20 mg/mL) and amphotericin B (250 ng/mL), at 37°C in 5% CO 2 /21% O 2 . All tissue culture reagents were purchased from Sigma Aldrich.
SH-SY5Y cells were transiently transfected with siRNA directed against ECE-1 or ECE-2 using the Amaxa Cell Line Nucleofactor Kit V (Lonza, Basel, Switzerland) using program G-004 on a Nucleofactor device (Lonza). In brief, cells were cultured for 3-4 days until 80% confluent and electroporation was performed on~1.8 9 10 6 cells, which were nucleofected with siRNA targeted against ECE-1 (100 nM) or ECE-2 (30 nM) (Life Technologies, Warrington, UK) and seeded overnight in a 6-well plate. The conditioned medium was removed, centrifuged at 12,470 g for 10 min to remove any cellular debris, and stored at À80°C until used. The cells were subsequently washed in PBS, detached in PBS without magnesium and chloride (Sigma Aldrich), pelleted and lysed in non-denaturing Cell Lytic TM cell lysis buffer (Sigma Aldrich). The samples were centrifuged at 12,470 g for 15 min at 4°C and the supernatants aliquoted and stored at À80°C until used. Total protein level was determined using Total Protein Kit (Sigma Aldrich) and volumes were adjusted to add an equal amount of total protein per sample for measurement of ECE-1, ECE-2 and a-syn by sandwich ELISA, as described above. Each experiment was repeated in duplicate and performed on at least three separate occasions.
Double immunofluorescent labelling of ECE-1/ECE-2 and a-syn SH-SY5Y and SH-SY5Y-a-syn cells were grown on poly-L-lysinecoated coverslips, washed in PBS 93, fixed in 4% paraformaldehyde for 10 min, further washed in PBS and blocked for 30 min in PBS with 0.5% triton-X100 and 5% horse serum (Millipore, Nottingham, UK). Immunofluorescent labelling was firstly optimized for a-syn using mouse monoclonal a-syn (syn-1) (2.5 lg/mL) (BD, Oxford, UK) as previously described (Miners et al. 2014a) . ECE-1 (goat polyclonal anti-ECE-1; R&D systems, Cambridge, UK) and ECE-2 (goat polyclonal ECE-2; R&D systems) immunofluorescence was optimized and a panel of established endolysosomal markers (New England Biolabs, Herts, UK) was used according to the manufacturer's guidelines. For double-immunofluorescence we added antibody pairs for 1 h at 21°C, followed by Alexa-fluor-488 and -555 (Invitrogen, Carlsbad, CA, USA, Life Technologies, Paisley, UK) at 1 : 1000 for 1 h at 21°C in the dark. Images were acquired under an 9100 objective with a confocal scanning laser microscope (Nikon UK Ltd, Surrey, UK).
Proximity ligation assay
An in situ proximity ligation assay was performed using a Duolink kit as per manufacturer's guidelines (Sigma Aldrich). In brief, SH-SY5Y cells were grown on poly-L-lysine-coated coverslips and fixed in paraformaldehyde as above. Mouse monoclonal a-syn (2.5 lg/ mL; BD) was used with either goat polyclonal ECE-1 (R&D systems) or goat polyclonal ECE-2 (R&D systems). For negative controls one of the antibodies for each pair was omitted. The experiments were repeated in triplicate.
Statistical analysis
Parametric statistical tests were used where possible for group comparisons (this required logarithmic transformation of the ECE-1 data to obtain a normal distribution). Unpaired t-test were used for group comparisons. Pearson analysis was used to assess the correlation between pairs of variables. Statistical tests were performed with the help of SPSS version 23. p-values < 0.05 were considered statistically significant. A schematic summarizing the experimental design is shown in Figure S1 .
Results
ECE-1 and ECE-2 cleave a-syn in vitro
Recombinant human ECE-1 and ECE-2 cleaved full-length recombinant human a-syn resulting in a reduction in monomeric a-syn (~16kDa band) in a time- (Fig. 1 ) and dose-dependent (Fig. 2) manner. ECE-1 and ECE-2 mediated a-syn cleavage resulted in a greater than 50% reduction in the density of monomeric a-syn at 5 min with almost Fig. 1 Time course of endothelin-converting enzyme 1 (ECE-1) and ECE-2 cleavage of a-syn in vitro. Full-length wild-type recombinant human a-syn (5 ng) was incubated with recombinant human ECE-1 and ECE-2 (50 ng) in either distilled water or phosphate-buffered saline (PBS) and incubated at 37°C with shaking for 18 h. Samples were taken at various time-points and transferred to a nitrocellulose membrane followed by western blotting with mouse monoclonal antia-syn (syn-1). Two independent experiments were performed (n = 2). The band density of monomeric a-syn (~16 kDa) was measured at each time point, and the percentage change calculated relative to the density at 0 min (i.e. uncleaved a-syn, assigned a value of 100%). complete cleavage observed at~2 h (Fig. 1) . ECE-1 and ECE-2 (50-1.56 ng) cleaved human a-syn in a dosedependent manner (Fig. 2) . ECE-1 and ECE-2 cleaved a-syn at a mildly acidic pH resulting in a similar timedependent reduction in monomeric a-syn observed at a neutral pH (Fig. 3) . In comparison to ECE-1, recombinant human a-syn was not cleaved by recombinant human neprilysin, human angiotensin-converting enzyme-1, or human insulin-degrading enzyme ( Figure S2 ). ECE-mediated cleavage of recombinant human a-syn was inhibited in the presence of phosphoramidon (100 lM) ( Figure S3 ).
ECE-1 and ECE-2 regulate intracellular and extracellular a-syn level in vitro
To assess the possible functional significance of ECE in the homeostasis of a-syn, we measured the level of a-syn in SH-SY5Y cells following transient siRNA-mediated knock-down of ECE-1 or ECE-2. A modest reduction in the expression of ECE-1 (~25% reduction in ECE-1 protein level as measured by ELISA) resulted in significantly increased endogenous asyn level, both in the cell lysate (~50% increase in a-syn level as measured by ELISA) and in the surrounding culture medium (~40% increase in a-syn level as measured by ELISA) (Fig. 4a-c) . siRNA-mediated transient knockdown of ECE-2 caused a~60% reduction in ECE-2 protein level as measured by ELISA, and produced a significant increase in a-syn in the cell lysate (~30% increase in a-syn level as measured by ELISA). A non-significant increase in a-syn level was also measured in the surrounding medium (~20% increase in a-syn level as measured by ELISA) (Fig. 4d-f ).
ECE-1 and ECE-2 interact with a-syn within the endolysosomal pathway Co-localization of ECE-1 with a-syn was observed in SH-SY5Y cells and SH-SY5Y cells over-expressing human a-syn (SH-SY5Y-a-syn) (Fig. 5) . a-syn was endogenously expressed throughout the cytoplasm in SH-SY5Y cells (Fig. 5a ) and was increased in SH-SY5Y-a-syn cells (Fig. 5d) . ECE-1 was abundantly expressed throughout the cytoplasm ( Fig. 5b and e) where it co-localized with markers of maturing endosomes (mannose-6-phosphate receptor and Rab 7) ( Figure S4 ). ECE-1 also co-localized with a-syn ( Fig. 5c and f) and the amount of co-localization between ECE-1 and a-syn appeared visually greater within individual cells in SH-SY5Y-a-syn cells (Fig. 5f ). ECE-2 was also distributed throughout the cytoplasm but had a more punctate appearance ( Fig. 6b and e) [a small degree of co-localization was observed between ECE-2 and markers of early endosomes -early endosome autoantigen 1 and Rab 5 ( Figure S5) ]. Merged images show focal points of co-localization between ECE-2 and a-syn in SHSY-5Y (Fig. 6c) and SH-SY5Y-a-syn cells (Fig. 6f) . To confirm that ECE-1 and ECE-2 were localized within close proximity of a-syn, we used a proximity ligation assay (Fig. 7 ). These images demonstrate co-localization of both ECEs with a-syn, at a distance of 15 nm or less. As with double immunofluorescence studies co-localization of asyn with ECE-1 was more apparent than with ECE-2.
ECE-1 and ECE-2 level is reduced in DLB and correlates inversely with a-syn-P129
To determine whether the levels of ECEs are altered in Lewy body disease and potentially contribute to the pathogenesis of DLB we measured ECE-1, ECE-2, a-syn and a-syn-P129 levels in cingulate cortex from DLB and control brains by ELISA. We showed previously that a-syn-P129 is a reliable indicator of severity of Lewy body pathology (Miners et al. Fig. 2 Dose-dependent cleavage of a-syn by endothelin-converting enzyme 1 (ECE-1) and ECE-2 in vitro. Full-length recombinant a-syn, was incubated with recombinant human ECE-1 and ECE-2 at various concentrations (50-1.25 ng) in distilled water for 10 min before samples were transferred to a nitrocellulose membrane followed by western blotting with mouse monoclonal anti-a-syn (syn-1). Two independent experiments were performed (n = 2). For each experiment, the band density of monomeric a-syn (~16 kDa) was measured and the percentage change calculated relative to the control (i.e. 0 ng of ECE). 2014a; Swirski et al. 2014) . ECE-1 and ECE-2 levels were significantly reduced in DLB compared to age-matched controls (Fig. 8a-b) . Reduced ECE-1 and ECE-2 levels correlated inversely with increasing a-syn-P129 level across the cohorts (Fig. 8c-d) .
Discussion
Endothelin-converting enzymes are expressed throughout the brain and are involved in the hydrolysis of a range of biologically diverse peptides. Alterations in ECE activity have been suggested to be involved in the pathogenesis of Alzheimer's disease, as ECEs were shown to cleave amyloidb (Ab) (Eckman et al. 2001) , the levels of which are elevated in ECE-knockout mice (Eckman et al. 2003) . Here we have shown for the first time that ECEs cleave a-syn and that knockdown of either ECE-1 or ECE-2 increases the amount of both intracellular and extracellular a-syn. We have also shown that ECEs interact with a-syn within the endolysosomal pathway in SH-SY5Y cells. We have shown too that ECE-1 and ECE-2 levels are significantly reduced in cingulate cortex (an area with a predilection for a-syn accumulation in Lewy bodies in DLB Miners et al. 2014a; Swirski et al. 2014) in post-mortem brain tissue from people with DLB, and that the concentration of a-syn-P129 (which accounts for~90% of the a-syn within Lewy bodies Fujiwara et al. 2002; Anderson et al. 2006 ) correlated with the extent of reduction in ECEs in the same tissue samples. Together these findings suggest a novel role for ECEs in the homeostasis of a-syn and suggest that deficient enzyme activity may contribute to the pathogenesis of DLB, although further work is required.
ECEs are expressed throughout the brain. ECE-1 is expressed abundantly in endothelial cells but has also been identified within non-vascular cells within the CNS such as pyramidal neurons, cerebellar Purkinje cells and astrocytes (Naidoo et al. 2004; Palmer et al. 2010) . Of the four isoforms, ECE-1a and ECE-1c are mainly expressed at the plasma membrane, whereas ECE-1d and ECE-1b are localized to intracellular compartments including the recycling and late endosomes (Schweizer et al. 1997; Azarani et al. 1998; Muller et al. 2003) . ECE-2 is expressed predominantly by pyramidal neurons in the CNS (Palmer et al. 2009 ) and has four isoforms that are expressed intracellularly. ECE-1 and ECE-2 degrades a variety of neuropeptides within endosomes and are responsible for regulating receptor recycling during neuropeptide signalling Roosterman et al. 2007 Roosterman et al. , 2008 Gupta et al. 2015) .
It is becoming increasingly clear that disturbances in clearance play a major role in the accumulation of a range of aggregation-prone, disease-related proteins within the brain. Many of the pathways involved in the clearance of asyn are dysregulated in Lewy body diseases (reviewed in Webb et al. 2003; Deleidi and Maetzler 2012; EbrahimiFakhari et al. 2012; Xilouri et al. 2013) . There is strong evidence that dysregulation of the ubiquitin-proteosomal pathway and the autophagy-lysosomal system (cathepsin D is an important mediator of degradation of a-syn within the lysosome) (Qiao et al. 2008; Sevlever et al. 2008; Cullen et al. 2009 ) are involved in the accumulation of a-syn in Lewy body diseases. Another probable contributor to this accumulation is a reduction in CAPN1 and KLK6, two recently identified a-syn-degrading proteases, the levels of Fig. 3 Time-course of endothelin-converting enzyme 1 (ECE-1) and ECE-2 cleavage of a-syn at mildy acidic pH in vitro. Full-length asyn was incubated with recombinant human ECE-1 (50 ng, pH 6.0) and ECE-2 (50 ng, pH 5.5) at a mildly acidic pH and incubated at 37°C with shaking for 18 h. Samples were taken at different timepoints and analysed by western blot with mouse monoclonal anti-asyn (syn-1). Two independent experiments were performed (n = 2). The relative band density of monomeric a-syn (~16 kDa) was measured at each time point. For each experiment, the percentage change at each time point was calculated relative to 0 min (i.e. uncleaved a-syn). and ECE-2 regulate an intracellular and extracellular pool of a-syn in SH-SY5Y cells. (a-c) siRNA-mediated knockdown of ECE-1 (~25% reduction) resulted in increased a-syn levels in the cell lysate (~50%) and in the cell medium (~40%) of SH-SY5Y cells. (d-f) siRNAmediated knockdown of ECE-2 (~60% reduction) resulted in increased a-syn levels in the cell lysate (~30%) and, although not significant, increased a-syn level within the cell medium (~20%). ECE-1, ECE-2 and a-syn level were measured by sandwich ELISA in cell lysates adjusted for total protein. Four independent experiments were performed (n = 4). Measurements were performed in duplicate for each experiment and the percentage change calculated relative to the control (i.e. untreated cells expressed as 100%). The bars show the mean AE standard deviation of measurements after pooling the measurements from the four independent experiments. Images were acquired under a 960 objective with a confocal scanning laser microscope. Nuclei were stained blue with DAPI. Two independent experiments were performed (n = 2) and representative images shown from a single experiment.
which we recently reported to be reduced within the cingulate cortex in DLB and were inversely correlated with the level of a-syn phosphorylated at Ser129 (Miners et al. 2014a) , as was the case for the concentration of ECEs in this study.
Discrete intracellular pools of a-syn have been detected in early, late and recycling endosomes (Lee et al. 2008; Hasegawa et al. 2011) , multi-vesicular bodies and lysosomes (Boassa et al. 2013) , autophagic vesicles following chaperone-mediated autophagy (Mak et al. 2010) and exosomes . Dysregulation of the endo-lysosomal and autophagic systems, which occurs early in the development of Lewy body diseases, has been implicated in the accumulation, vesicular spread and trans-neuronal propagation of pathogenic a-syn (Mougenot et al. 2011 (Mougenot et al. , 2012 Luk et al. 2012; Masuda-Suzukake et al. 2013) . Our data show that ECEs interact with a-syn within several intracellular locations that impact on the secretion of a-syn, although further work is required to confirm this. Our findings are similar to the observations of Pacheco-Quinto and Eckman (2013) who demonstrated that ECEs degrade discrete pools of vesicular Ab: ECE-2 cleaved an intracellular pool of Ab which was produced and degraded within the autophagic and endolysosomal pathway, whereas ECE-1 (although contributing to both pathways) predominantly degraded a pool of Ab destined for secretion. A recent study demonstrated that an increase in KLK6, which is synthesized as an inactive zymogen and secreted extracellularly whereupon it is activated and degrades extracellular a-syn (Tatebe et al. 2010) , could also reduce the transcellular spread of pathogenic a-syn (Yamashiro et al. 1997) . Further work is required to determine whether ECEs, particularly ECE-1 might influence the transcellular spread and CNS accumulation of a-syn as postulated for KLK6.
In this study, we have shown that ECE-1 and ECE-2 degrade full-length monomeric a-syn at both a neutral and mildly acidic pH in a time-and dose-dependent manner. Over 50% reduction in monomeric a-syn was observed in the first 5 min with complete degradation observed at 2 h. This is inkeeping with relatively rapid CTSD (Sevlever et al. 2008 ) Fig. 8 Endothelin-converting enzyme 1 (ECE-1) and ECE-2 levels were reduced in human post-mortem brain tissue the cingulate cortex in dementia with Lewy bodies (DLB). (a and b) Reduced ECE-1 and ECE-2 (measured by sandwich ELISA) in the cingulate cortex, a region with a predilection to Lewy body pathology, in DLB. Measurements were performed in triplicate for each individual case (represented by a dot). The bars show the mean AE standard deviation. The ECE-1 data set was skewed and so was log-transformed and an unpaired t-test performed after transformation. The ECE-2 data set was normally distributed and an unpaired t-test was performed. (c and d) Scatterplots showing ECE-1 and ECE-2 level correlated inversely with the level of a-syn phosphorylated at Ser129 (a marker of Lewy body pathology) measured by sandwich ELISA in triplicate. Each dot represents an individual brain. The best-fit linear regression line and 95% confidence interval are superimposed. Pearson's test was used for correlation analysis. *p < 0.05; **p < 0.01; ***p < 0.001 and CAPN-1 mediated degradation of a-syn (Dufty et al. 2007 ) in contrast to slower and incomplete KLK6-mediated cleavage (6-24 h) (Kasai et al. 2008) . To fully understand the potential role of ECE-1 and -2 in the pathogenesis of Lewy body diseases, such as DLB, however, requires further mapping of ECE-mediated a-syn cleavage sites and characterization of the cleavage fragments within human brain tissue and in animal studies. It has been established that cleavage within the NAC (non-amyloidogenic component) domain reduces the aggregation of full-length wild-type a-syn, as shown for KLK6 (Kasai et al. 2008) . C-terminal truncation on the other hand, as shown for CAPN1 (Mishizen-Eberz et al. 2005; Dufty et al. 2007) , and MMP-3 (Sung et al. 2005; Choi et al. 2011 ) mediated cleavage of fibrillary a-syn produces fragments that accelerate the aggregation of a-syn. CAPN1-mediated cleavage of a-syn has been postulated to accelerate disease (Higuchi et al. 2012; Yamashima 2013) , whereas KLK6-mediated cleavage (Spencer et al. 2013 ) and CTSD cleavage (Qiao et al. 2008; Cullen et al. 2009 ) is protective. It also remains to be determined whether diseaseassociated mutant forms of a-syn (such as those carrying A53T or A30P mutations), or phosphorylated forms of a-syn, are resistant to ECE-mediated degradation as previously shown for KLK6 and CAPN1 (Iwata et al. 2003; MishizenEberz et al. 2003; Kasai et al. 2008) . Lastly, the ability of ECE to cleave such a relatively large substrate (Mr of a-syn is 14 kDa) compared to most neuropeptides and beta amyloid (between 1 and 4 KDa) is also unusual and is not shared by closely related metallo-endopeptidases such as neprilysin and insulin-degrading enzyme.
In conclusion, we present novel evidence that ECEs cleave and degrade a-syn in vitro and may contribute to the homeostasis of a-syn and the pathogenesis of Lewy body diseases. 
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